A Randomized, Parallel-group Treatment, Phase 2, Double-blind Pilot Study to Investigate the Efficacy and Safety of Elinzanetant Compared With Placebo for Treatment of Sleep Disturbances Associated With Menopause

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elinzanetant (Primary)
Indications Sleep disorders
Focus Registrational; Therapeutic Use
Acronyms NIRVANA
Sponsors Bayer

Most Recent Events

13 Dec 2024 Status changed from active, no longer recruiting to completed.
04 Sep 2024 According to a Bayer Media Release, design of this NIRVANA study will be presented by Christian Seitz in annual meeting of The Menopause Society (TMS) which takes place on 12th September 2024, in Chicago, IL, United States.
15 Aug 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight